About this Journal Submit a Manuscript Table of Contents
ISRN Veterinary Science
Volume 2013 (2013), Article ID 167521, 8 pages
http://dx.doi.org/10.1155/2013/167521
Review Article

Recent Developments in Liposome-Based Veterinary Therapeutics

1Biomedical Sciences, 218 Queen’s Quay West, Toronto, ON, Canada M5J 2Y6
2Animal Biology, 7454 Conservation Road, Guelph, ON, Canada N1H 6J2

Received 7 August 2013; Accepted 11 September 2013

Academic Editors: Y.-F. Chang and M. H. Kogut

Copyright © 2013 Hassan Sadozai and Dorsa Saeidi. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. D. J. Brayden, E. J. M. Oudot, and A. W. Baird, “Drug delivery systems in domestic animal species,” Handbook of Experimental Pharmacology, vol. 199, pp. 79–112, 2010. View at Publisher · View at Google Scholar · View at Scopus
  2. C. Underwood and A. W. van Eps, “Nanomedicine and veterinary science: the reality and the practicality,” Veterinary Journal, vol. 193, no. 1, pp. 12–23, 2012. View at Publisher · View at Google Scholar · View at Scopus
  3. J. M. Irache, I. Esparza, C. Gamazo, M. Agüeros, and S. Espuelas, “Nanomedicine: novel approaches in human and veterinary therapeutics,” Veterinary Parasitology, vol. 180, no. 1-2, pp. 47–71, 2011. View at Publisher · View at Google Scholar · View at Scopus
  4. S. K. Sahoo and V. Labhasetwar, “Nanotech approaches to drug delivery and imaging,” Drug Discovery Today, vol. 8, no. 24, pp. 1112–1120, 2003. View at Publisher · View at Google Scholar · View at Scopus
  5. V. P. Torchilin, “Recent advances with liposomes as pharmaceutical carriers,” Nature Reviews Drug Discovery, vol. 4, no. 2, pp. 145–160, 2005. View at Publisher · View at Google Scholar · View at Scopus
  6. T. Suzuki, M. Ichihara, K. Hyodo, et al., “Accelerated blood clearance of PEGylated liposomes containing doxorubicin upon repeated administration to dogs,” International Journal of Pharmaceutics, vol. 436, no. 1-2, pp. 636–643, 2012. View at Publisher · View at Google Scholar
  7. J. S. Rose, J. M. Neal, and D. J. Kopacz, “Extended-duration analgesia: update on microspheres and liposomes,” Regional Anesthesia and Pain Medicine, vol. 30, no. 3, pp. 275–285, 2005. View at Publisher · View at Google Scholar · View at Scopus
  8. S. C. Basu and M. Basu, Liposome Methods and Protocols, Humana Press, Totowa, NJ, USA, 2002.
  9. A. N. Lukyanov, T. A. Elbayoumi, A. R. Chakilam, and V. P. Torchilin, “Tumor-targeted liposomes: doxorubicin-loaded long-circulating liposomes modified with anti-cancer antibody,” Journal of Controlled Release, vol. 100, no. 1, pp. 135–144, 2004. View at Publisher · View at Google Scholar · View at Scopus
  10. K. Kono, “Thermosensitive polymer-modified liposomes,” Advanced Drug Delivery Reviews, vol. 53, no. 3, pp. 307–319, 2001. View at Publisher · View at Google Scholar · View at Scopus
  11. M. Ferrari, “Cancer nanotechnology: opportunities and challenges,” Nature Reviews Cancer, vol. 5, no. 3, pp. 161–171, 2005. View at Publisher · View at Google Scholar · View at Scopus
  12. K. H. Bae, H. J. Chung, and T. G. Park, “Nanomaterials for cancer therapy and imaging,” Molecules and Cells, vol. 31, no. 4, pp. 295–302, 2011. View at Publisher · View at Google Scholar · View at Scopus
  13. S. Egusquiaguirre, M. Igartua, R. Hernandez, and J. Pedraz, “Nanoparticle delivery systems for cancer therapy: advances in clinical and preclinical research,” Clinical and Translational Oncology, vol. 14, no. 2, pp. 83–93, 2012. View at Publisher · View at Google Scholar
  14. D. M. Vail, E. G. MacEwen, I. D. Kurzman et al., “Liposome-encapsulated muramyl tripeptide phosphatidylethanolamine adjuvant immunotherapy for splenic hemangiosarcoma in the dog: a randomized multi-institutional clinical trial,” Clinical Cancer Research, vol. 1, no. 10, pp. 1165–1170, 1995. View at Scopus
  15. I. Judson, J. A. Radford, M. Harris et al., “Randomised phase II trial of pegylated liposomal doxorubicin (DOXIL/CAELYX) versus doxorubicin in the treatment of advanced or metastatic soft tissue sarcoma: a study by the EORTC Soft Tissue and Bone Sarcoma Group,” European Journal of Cancer, vol. 37, no. 7, pp. 870–877, 2001. View at Publisher · View at Google Scholar · View at Scopus
  16. M. L. Hauck, S. M. La Rue, W. P. Petros et al., “Phase I trial of doxorubicin-containing low temperature sensitive liposomes in spontaneous canine tumors,” Clinical Cancer Research, vol. 12, no. 13, pp. 4004–4010, 2006. View at Publisher · View at Google Scholar · View at Scopus
  17. M. Kleiter, A. Tichy, M. Willmann, M. Pagitz, and B. Wolfesberger, “Concomitant liposomal doxorubicin and daily palliative radiotherapy in advanced feline soft tissue sarcomas,” Veterinary Radiology and Ultrasound, vol. 51, no. 3, pp. 349–355, 2010. View at Publisher · View at Google Scholar · View at Scopus
  18. S. Hafeman, C. London, R. Elmslie, and S. Dow, “Evaluation of liposomal clodronate for treatment of malignant histiocytosis in dogs,” Cancer Immunology, Immunotherapy, vol. 59, no. 3, pp. 441–452, 2010. View at Publisher · View at Google Scholar · View at Scopus
  19. C. R. Safinya, K. Ewert, A. Anmad et al., “Cationic liposome-DNA complexes: from liquid crystal science to gene delivery applications,” Philosophical Transactions of the Royal Society A, vol. 364, no. 1847, pp. 2573–2596, 2006. View at Publisher · View at Google Scholar · View at Scopus
  20. G. Caracciolo and H. Amenitsch, “Cationic liposome/DNA complexes: from structure to interactions with cellular membranes,” European Biophysics, vol. 41, no. 10, pp. 815–829, 2012. View at Publisher · View at Google Scholar
  21. P. L. Felgner, T. R. Gadek, M. Holm et al., “Lipofection: a highly efficient, lipid-mediated DNA-transfection procedure,” Proceedings of the National Academy of Sciences of the United States of America, vol. 84, no. 21, pp. 7413–7417, 1987. View at Scopus
  22. M. Rogers and R. A. Rush, “Non-viral gene therapy for neurological diseases, with an emphasis on targeted gene delivery,” Journal of Controlled Release, vol. 157, no. 2, pp. 183–189, 2012. View at Publisher · View at Google Scholar · View at Scopus
  23. L. W. U'Ren, B. J. Biller, R. E. Elmslie, D. H. Thamm, and S. W. Dow, “Evaluation of a novel tumor vaccine in dogs with hemangiosarcoma,” Journal of Veterinary Internal Medicine, vol. 21, no. 1, pp. 113–120, 2007. View at Publisher · View at Google Scholar · View at Scopus
  24. D. Kamstock, A. Guth, R. Elmslie et al., “Liposome-DNA complexes infused intravenously inhibit tumor angiogenesis and elicit antitumor activity in dogs with soft tissue sarcoma,” Cancer Gene Therapy, vol. 13, no. 3, pp. 306–317, 2006. View at Publisher · View at Google Scholar · View at Scopus
  25. A. Schroeder, D. A. Heller, M. M. Winslow et al., “Treating metastatic cancer with nanotechnology,” Nature Reviews Cancer, vol. 12, no. 1, pp. 39–50, 2012. View at Publisher · View at Google Scholar · View at Scopus
  26. Z. Wang, Y. Yu, W. Dai, et al., “The use of a tumor metastasis targeting peptide to deliver doxorubicin-containing liposomes to highly metastatic cancer,” Biomaterials, vol. 33, no. 33, pp. 8451–8460, 2012. View at Publisher · View at Google Scholar
  27. J. M. Cox and A. Pavic, “Advances in enteropathogen control in poultry production,” Journal of Applied Microbiology, vol. 108, no. 3, pp. 745–755, 2010. View at Publisher · View at Google Scholar · View at Scopus
  28. P. Nordly, H. B. Madsen, H. M. Nielsen, and C. Foged, “Status and future prospects of lipid-based particulate delivery systems as vaccine adjuvants and their combination with immunostimulators,” Expert Opinion on Drug Delivery, vol. 6, no. 7, pp. 657–672, 2009. View at Publisher · View at Google Scholar · View at Scopus
  29. T. Storni, T. M. Kündig, G. Senti, and P. Johansen, “Immunity in response to particulate antigen-delivery systems,” Advanced Drug Delivery Reviews, vol. 57, no. 3, pp. 333–355, 2005. View at Publisher · View at Google Scholar · View at Scopus
  30. N. Csaba, M. Garcia-Fuentes, and M. J. Alonso, “Nanoparticles for nasal vaccination,” Advanced Drug Delivery Reviews, vol. 61, no. 2, pp. 140–157, 2009. View at Publisher · View at Google Scholar · View at Scopus
  31. K. S. Korsholm, P. L. Andersen, and D. Christensen, “Cationic liposomal vaccine adjuvants in animal challenge models: overview and current clinical status,” Expert Review of Vaccines, vol. 11, no. 5, pp. 561–577, 2013.
  32. W. Li, S. Watarai, T. Iwasaki, and H. Kodama, “Suppression of Salmonella enterica serovar Enteritidis excretion by intraocular vaccination with fimbriae proteins incorporated in liposomes,” Developmental and Comparative Immunology, vol. 28, no. 1, pp. 29–38, 2004. View at Publisher · View at Google Scholar · View at Scopus
  33. M. E. St. Louis, D. L. Morse, M. E. Potter et al., “The emergence of grade A eggs as a major source of Salmonella enteritidis infections: new implications for the control of salmonellosis,” Journal of the American Medical Association, vol. 259, no. 14, pp. 2103–2107, 1988. View at Scopus
  34. K. Yaguchi, T. Ohgitani, T. Noro, T. Kaneshige, and Y. Shimizu, “Vaccination of chickens with liposomal inactivated avian pathogenic Escherichia coli (APEC) vaccine by eye drop or coarse spray administration,” Avian Diseases Digest, vol. 4, no. 2, p. e19, 2009.
  35. K. Zhao, G. Chen, X. Shi, et al., “Preparation and efficacy of a live newcastle disease virus vaccine encapsulated in chitosan nanoparticles,” PLoS One, vol. 7, no. 12, Article ID e53314, 2012.
  36. E. B. Onuigbo, V. C. Okore, K. C. Ofokansi, et al., “Preliminary evaluation of the immunoenhancement potential of Newcastle disease vaccine formulated as a cationic liposome,” Avian Pathology, vol. 41, no. 4, pp. 355–360, 2012. View at Publisher · View at Google Scholar
  37. D. J. Alexander, “Newcastle disease in the European Union 2000 to 2009,” Avian Pathology, vol. 40, no. 6, pp. 547–558, 2012.
  38. E. R. Pfefferkorn, “Interferon gamma blocks the growth of Toxoplasma gondii in human fibroblasts by inducing the host cells to degrade tryptophan,” Proceedings of the National Academy of Sciences of the United States of America, vol. 81, no. 3, pp. 908–912, 1984. View at Scopus
  39. E. Hiszczyńska-Sawicka, H. Li, J. Boyu Xu et al., “Induction of immune responses in sheep by vaccination with liposome-entrapped DNA complexes encoding Toxoplasma gondii MIC3 gene,” Polish Journal of Veterinary Sciences, vol. 15, no. 1, pp. 3–9, 2012. View at Publisher · View at Google Scholar · View at Scopus
  40. J. R. Schmidt, L. Krugner-Higby, T. D. Heath, R. Sullivan, and L. J. Smith, “Epidural administration of liposome-encapsulated hydromorphone provides extended analgesia in a rodent model of stifle arthritis,” Journal of the American Association for Laboratory Animal Science, vol. 50, no. 4, pp. 507–512, 2011. View at Scopus
  41. M. Rathbone and D. Brayden, “Controlled release drug delivery in farmed animals: commercial challenges and academic opportunities,” Current Drug Delivery, vol. 6, no. 4, pp. 383–390, 2009. View at Publisher · View at Google Scholar · View at Scopus
  42. J. S. Rose, J. M. Neal, and D. J. Kopacz, “Extended-duration analgesia: update on microspheres and liposomes,” Regional Anesthesia and Pain Medicine, vol. 30, no. 3, pp. 275–285, 2005. View at Publisher · View at Google Scholar · View at Scopus
  43. G. J. Grant, J. Lax, L. Susser, M. Zakowski, T. E. Weissman, and H. Turndorf, “Wound infiltration with liposomal bupivacaine prolongs analgesia in rats,” Acta Anaesthesiologica Scandinavica, vol. 41, no. 2, pp. 204–207, 1997. View at Scopus
  44. B. Richard, P. Newton, L. Ott et al., “The safety of EXPAREL (bupivacaine liposome injectable suspension) administered by peripheral nerve block in rabbits and dogs,” Journal of Drug Delivery, vol. 2012, Article ID 962101, 10 pages, 2012. View at Publisher · View at Google Scholar
  45. J. R. Paul-Murphy, L. A. Krugner-Higby, R. L. Tourdot et al., “Evaluation of liposome-encapsulated butorphanol tartrate for alleviation of experimentally induced arthritic pain in green-cheeked conures (Pyrrhura molinae),” American Journal of Veterinary Research, vol. 70, no. 10, pp. 1211–1219, 2009. View at Publisher · View at Google Scholar · View at Scopus
  46. L. Krugner-Higby, L. Smith, B. Schmidt et al., “Experimental pharmacodynamics and analgesic efficacy of liposome-encapsulated hydromorphone in dogs,” Journal of the American Animal Hospital Association, vol. 47, no. 3, pp. 185–195, 2011. View at Publisher · View at Google Scholar · View at Scopus
  47. A. Livingston, “Pain and analgesia in domestic animals,” Handbook of Experimental Pharmacology, vol. 199, pp. 159–189, 2010. View at Publisher · View at Google Scholar · View at Scopus
  48. D. D. Frisbie, C. W. McIlwraith, C. E. Kawcak, N. M. Werpy, and G. L. Pearce, “Evaluation of topically administered diclofenac liposomal cream for treatment of horses with experimentally induced osteoarthritis,” American Journal of Veterinary Research, vol. 70, no. 2, pp. 210–215, 2009. View at Publisher · View at Google Scholar · View at Scopus
  49. J. Szebeni, C. R. Alving, L. Rosivall et al., “Animal models of complement-mediated hypersensitivity reactions to liposomes and other lipid-based nanoparticles,” Journal of Liposome Research, vol. 17, no. 2, pp. 107–117, 2007. View at Publisher · View at Google Scholar · View at Scopus
  50. P. I. Menzies, “Control of Important Causes of Infectious Abortion in Sheep and Goats,” Veterinary Clinics of North America, vol. 27, no. 1, pp. 81–93, 2011. View at Publisher · View at Google Scholar · View at Scopus
  51. J. W. Card, T. S. Jonaitis, S. Tafazoli, and B. A. Magnuson, “An appraisal of the published literature on the safety and toxicity of food-related nanomaterials,” Critical Reviews in Toxicology, vol. 41, no. 1, pp. 22–51, 2011. View at Publisher · View at Google Scholar · View at Scopus
  52. B. A. Yegin and A. Lamprecht, “Lipid nanocapsule size analysis by hydrodynamic chromatography and photon correlation spectroscopy,” International Journal of Pharmaceutics, vol. 320, no. 1-2, pp. 165–170, 2006. View at Publisher · View at Google Scholar · View at Scopus
  53. W. T. Al-Jamal and K. Kostarelos, “Liposomes: from a clinically established drug delivery system to a nanoparticle platform for theranostic nanomedicine,” Accounts of Chemical Research, vol. 44, no. 10, pp. 1094–1104, 2011. View at Publisher · View at Google Scholar · View at Scopus